Abstract:Immunoengineering continues to revolutionize healthcare, generating new approaches for treating previously intractable diseases, particularly in regard to cancer immunotherapy. In joint diseases, such as osteoarthritis (OA) and rheumatoid arthritis (RA), biomaterials and anti-cytokine treatments have previously been at that forefront of therapeutic innovation. However, while many of the existing anti-cytokine treatments are successful for a subset of patients, these treatments can also pose severe risks, adverse events and off-target effects due to continuous delivery at high dosages or a lack of disease-specific targets. The inadequacy of these current treatments has motivated the development of new immunoengineering strategies that offer safer and more efficacious alternative therapies through the precise and controlled targeting of specific upstream immune responses, including direct and mechanistically-driven immunoengineering approaches. Advances in the understanding of the immunomodulatory pathways involved in musculoskeletal disease, in combination with the growing emphasis on personalized medicine, stress the need for carefully considering the delivery strategies and therapeutic targets when designing therapeutics to better treat RA and OA. Here, we focus on recent advances in biomaterial and cell-based immunomodulation, in combination with genetic engineering, for therapeutic applications in joint diseases. The application of immunoengineering principles to the study of joint disease will not only help to elucidate the mechanisms of disease pathogenesis but will also generate novel disease-specific therapeutics by harnessing cellular and biomaterial responses. STATEMENT OF SIGNIFICANCE: It is now apparent that joint diseases such as osteoarthritis and rheumatoid arthritis involve the immune system at both local (i.e., within the joint) and systemic levels. In this regard, targeting the immune system using both biomaterial-based or cellular approaches may generate new joint-specific treatment strategies that are well-controlled, safe, and efficacious. In this review, we focus on recent advances in immunoengineering that leverage biomaterials and/or genetically engineered cells for therapeutic applications in joint diseases. The application of such approaches, especially synergistic strategies that target multiple immunoregulatory pathways, has the potential to revolutionize our understanding, treatment, and prevention of joint diseases.

The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases

A new age of precision gene therapy

Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases

The role of gene therapy in regenerative surgery: updated insights

Recent Therapeutic Gene Editing Applications to Genetic Disorders

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

The Interface of Gene Editing with Regenerative Medicine

Challenges and progress related to gene editing in rare skin diseases

Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectives

Successes and challenges in clinical gene therapy

Gene and cell therapy of human genetic diseases: Recent advances and future directions

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

Progress Toward a Gene Therapy for Arthritis

Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis

Current developments of gene therapy in human diseases

Immunoengineering the next generation of arthritis therapies

Toward gene therapy in rheumatoid arthritis

Therapeutic Potential of Gene Therapy for Gastrointestinal Diseases: Advancements and Future Perspectives

Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing

What a Clinician Needs to Know About Genome Editing: Status and Opportunities for Inborn Errors of Immunity

Rare immune diseases paving the road for genome editing-based precision medicine